Dr. Muggia on Targeted Therapies in Ovarian Cancer

Partner | Cancer Centers | <b>Perlmutter Cancer Center at NYU Langone</b>

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

NYU Langone

Franco M. Muggia, MD, Franco M. Muggia, MD, The Anne Murnick Cogan and David H. Cogan Professor of Oncology, Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

Muggia says drug development in ovarian cancer has not been easy, resulting in a lack of targeted therapies. Physicians rely on a chemotherapy regimen to treat patients with ovarian cancer that eliminates advanced disease about 80-90% of the time. However, Muggia says, the disease eventually comes back.

Muggia says there is a need to improve treatment for ovarian cancer. BRCA and PARP targets have proven to be good targets to develop further.